Vnitr Lek 2007, 53(3):293-299

Effectiveness of anti-resorption therapies of postmenopausal osteoporosis

J. Štěpán
III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA

The aim of this article is to justify a need for evaluation of the absolute risk of fractures, to compare efficacy of anti-resorptive therapies as indicated by large clinical trials, and to review currently available methods to assess efficacy of therapies in individual patients. It is emphasized that adherence to therapies is influenced not only by the individual bone efficacy and safety of the drug but also by beneficial impacts of the treatment on tissues other than bone.

Keywords: osteoporosis; fracture; BMD; biochemical markers; treatment

Received: December 13, 2006; Accepted: January 11, 2007; Published: March 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štěpán J. Effectiveness of anti-resorption therapies of postmenopausal osteoporosis. Vnitr Lek. 2007;53(3):293-299.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. NIH Consensus Development Panel. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-795. Go to original source... Go to PubMed...
    2. Kado DM, Duong T, Stone KL et al. Incident vertebral fractures and mortality in older women: a prospective study. Osteoporos Int 2003; 14: 589-594. Go to original source... Go to PubMed...
    3. Štěpán J, Payer J, Abrahámová J. Stratifikace léčby postmenopauzální osteoporózy. Prakt Lék 2004; 84: 500-506.
    4. Lufkin EG, Whitaker MD, Nickelsen T et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998; 13: 1747-1754. Go to original source... Go to PubMed...
    5. Maricic M, Adachi JD, Sarkar S et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002; 162: 1140-1143. Go to original source... Go to PubMed...
    6. Pols HA, Felsenberg D, Hanley DA et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999; 9: 461-468. Go to original source... Go to PubMed...
    7. Reginster J, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11: 83-91. Go to original source... Go to PubMed...
    8. Cranney A, Guyatt G, Griffith L et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570-578. Go to original source... Go to PubMed...
    9. Kado DM, Browner WS, Palermo L et al. Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999; 159: 1215-1220. Go to original source... Go to PubMed...
    10. Lindsay R, Silverman SL, Cooper C et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320-323. Go to original source... Go to PubMed...
    11. Štěpán J, Šmíd M, Prokeš M et al. Ekonomicke aspekty osteoporozy. Čas Lék Česko 1998; 137: 707-715.
    12. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-1541. Go to original source... Go to PubMed...
    13. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-2082. Go to original source... Go to PubMed...
    14. McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333-340. Go to original source... Go to PubMed...
    15. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999; 282: 1344-1352. Go to original source... Go to PubMed...
    16. Štěpán JJ: Algoritmus diagnostiky a léčby osteoporózy. Farmakoterapie 2005; 1: 485-494.
    17. Cummings SR, Palermo L, Browner W et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. JAMA 2000; 283: 1318-1321. Go to original source... Go to PubMed...
    18. Štěpán JJ, Zikán V. Calcitonin load test to assess the efficacy of salmon calcitonin. Clin Chim Acta 2003; 336: 49-55. Go to original source... Go to PubMed...
    19. Hochberg MC, Ross PD, Black D et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 1999; 42: 1246-1254. Go to original source...
    20. Štěpán J. Kvalita kosti: které účinky léčby můžeme monitorovat a co to předpokládá? Osteologicky Bull 2003; 8: 75-81.
    21. Garnero P. Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 2000; 11: 55-65. Go to original source... Go to PubMed...
    22. Gerdhem P, Ivaska KK, Alatalo SL et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2004; 19: 386-393. Go to original source... Go to PubMed...
    23. Borah B, Dufresne TE, Chmielewski PA et al. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 2004; 34: 736-746. Go to original source... Go to PubMed...
    24. Delmas PD, Genant HK, Crans GG et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003; 33: 522-532. Go to original source... Go to PubMed...
    25. Roy DK, Pye SR, Lunt M et al. Falls explain between-center differences in the incidence of limb fracture across Europe. Bone 2002; 31: 712-717. Go to original source... Go to PubMed...
    26. Dukas L, Schacht E, Stahelin HB. In elderly men and women treated for osteoporosis a low creatinine clearance of <65 ml/min is a risk factor for falls and fractures. Osteoporos Int 2005; 16: 1683-1690. Go to original source... Go to PubMed...
    27. Cramer JA, Amonkar MM, Hebborn A et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453-1460. Go to original source... Go to PubMed...
    28. Turbi C, Herrero Beaumont G et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. Clin Ther 2004; 26: 245-256. Go to original source... Go to PubMed...
    29. Martino S, Cauley JA, Barrett Connor E et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751-1761. Go to original source... Go to PubMed...
    30. Richer E, Lewis MA, Odvina CV et al. Reduction in normalized bone elasticity following long-term bisphosphonate treatment as measured by ultrasound critical angle reflectometry. Osteoporos Int 2005; 16: 1384-1392. Go to original source... Go to PubMed...
    31. Odvina CV, Zerwekh JE, Rao DS et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90: 1294-1301. Go to original source... Go to PubMed...
    32. Štěpán JJ, Burr DB, Pavo I et al. Prevalent fractures, low bone mineral density and ageing are associated with greater histomorphometric indicators of microdamage accumulation in postmenopausal women. J Bone Miner Res 2005; 20: S90-91.
    33. Caro JJ, Ishak KJ, Huybrechts KF et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15: 1003-1008. Go to original source... Go to PubMed...
    34. Bone HG, Hosking D, Devogelaer JP et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189-1199. Go to original source... Go to PubMed...
    35. Tremollieres FA, Pouilles JM, Ribot C. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporos Int 2001; 12: 385-390. Go to original source... Go to PubMed...
    36. Michalská D, Štěpán JJ, Basson BR et al. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2006; 91: 870-877. Go to original source... Go to PubMed...
    37. Silva MJ, Gibson LJ. Modeling the mechanical behavior of vertebral trabecular bone: effects of age-related changes in microstructure. Bone 1997; 21: 191-199. Go to original source... Go to PubMed...
    38. Ettinger B, San Martin J, Crans GG et al. Response of markers of bone turnover and bone density to teriparatide in postmenopausal women previously treated with an antiresorptive drug. J Bone Mineral Research 2003; 18: S15.
    39. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282: 637-645. Go to original source... Go to PubMed...
    40. Chesnut III CH, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-1249. Go to original source... Go to PubMed...
    41. Chesnut CH, Silverman S, Andriano K et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000; 109: 267-276. Go to original source... Go to PubMed...
    42. Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-468. Go to original source... Go to PubMed...
    43. Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816-2822. Go to original source... Go to PubMed...
    44. Liberman UA, Weiss SR, Broll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-1443. Go to original source... Go to PubMed...
    45. Watts NB, Harris ST, Genant HK et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73-79. Go to original source... Go to PubMed...
    46. McCloskey E, Selby P, Davies M et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 2004; 19: 728-736. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.